Izzeldin Najd Medical Elbashir

Dr. Izzeldin Najd Medical Elbashir

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2023 in International Journal of General Medicine
Verified
Journal Article
Open access
PDF file
IEIzzeldin Najd Medical Elbashir
Izzeldin Najd Medical Elbashir
TETagwa Yousif Elsayed
Tagwa Yousif Elsayed
Background and Purpose: Sickle cell disease (SCD) is an inherited hemoglobin disease affecting the red cells and causing hemolytic anemia. It is a very common, endemic disease in Sudan, particularly in the central and western areas of Sudan. Sickle cell anemia (SCA) is when the patient has beta-globin gene variant (Hb S variant). In this study, we screened the co-inheritance of hemoglobin O-Arab mutation among Sudanese sickle cell disease patients. Study Population and Methods: This cross-sectional study was conducted in the Sudan-Khartoum state from November 2016 to December 2021. Blood samples were collected from a random sample of the known sickle cell disease patients of Kordofan-central Sudan origin. Study-appropriate blood samples were subjected to complete blood count (CBC), hemoglobin capillary electrophoresis (CE) and molecular laboratory investigations. Initial laboratory investigations were done in Sudan, where the DNA sequencing technique was carried out at the Egyptian National Research Center (NRC)-Cairo-Egypt. Results: The final study’s main results revealed the presence of HB O-Arab genetic mutations among Sudanese Sickle cell disease patients, which estimated to be (5%) co-inherited mutations among our study population (Hb-O Arab; (HBB):c.364G>A (p.Glu122Lys)). Conclusion: The frequency of Hb-O Arab gene mutations was determined among Sudanese sickle cell disease patients, and the results have shown a (5%) frequency of Hb-O Arab mutation. The study result is the first molecular confirmation of co-inherited Hb-O Arab/sickle cell disease clinical condition in Sudan. The results raise the importance of extended studies of other sickle variant conditions.

1 March 2025 in Journal of Blood Medicine
Verified
Journal Article
Open access
PDF file
AAAyman Hussein Alfeel
Ayman Hussein Alfeel
TETagwa Yousif Elsayed
Tagwa Yousif Elsayed
AAAmmar Abdelmola
Ammar Abdelmola
PKPraveen Kumar
Praveen Kumar
Hussam Ali OsmanHussam Ali Osman
Hussam Ali Osman
IEIzzeldin Najd Medical Elbashir
Izzeldin Najd Medical Elbashir
Background and Purpose: Hemoglobinopathies are hereditary blood disorders affecting hemoglobin in red blood cells. This study aimed to determine the prevalence and types of hemoglobinopathies among newborns in Thumbay Teaching Hospital, Ajman-UAE, over three years (2020– 2022), and to analyze demographic trends. Method and Population: A laboratory-based retrospective cross-sectional study was conducted, involving 6,050 newborns screened using High-Performance Liquid Chromatography (HPLC). Results: We consider this study and its results as a new effort in the field of hemoglobinopathy research and management in Ajman in the United Arab Emirates. The final main findings revealed different hemoglobinopathy cases. In 2020 Two cases (2) involving Hb C variant were recorded, both of African origin (from Sudan and Egypt). The third case was Hb D variant which was also of African origin (Egypt). In 2021 no case was found. In 2022, the results showed a widespread of cases; A patient from Nigeria reported having Hb C, three cases of Hb D from Pakistan, two cases of Hb E trait from people in Bangladesh and India, one case of Hb S from Malawi, five cases of Hb S trait from people in Africa (two from Kenya, one from Tanzania), and two cases from Asian people from Yemen. The total number of detected hemoglobinopathies was 15 cases, accounting for a percentage of (0.2%). Conclusion: The study reveals a diverse presence of hemoglobinopathies among newborns in Ajman and underscores the importance of newborn screening programs to facilitate early diagnosis and treatment, particularly in regions with high genetic disorder prevalence. The study revealed almost an obvious African origin of Hb C and S cases and Asian one of Hb E and D cases.

9 November 2026 in Hemato
Verified
Journal Article
Open access
PDF file
Ahmed M. HjaziAhmed M. Hjazi
Ahmed M. Hjazi
AMAndrew Rizk Hakeem Matta
Andrew Rizk Hakeem Matta
MAMeshari meshal Almalki
Meshari meshal Almalki
AAArwa Mhd Safwan Almassri
Arwa Mhd Safwan Almassri
IEIzzeldin Najd Medical Elbashir
Izzeldin Najd Medical Elbashir
Which patients benefit from carfilzomib in multiple myeloma depends on the regimen, the comparator and the treatment phase. This critical narrative review integrates randomised trials, selected translational and observational studies, guidance, and targeted source verification through 16 October 2026. Frontline substitution trials, including ENDURANCE and CLARION, did not demonstrate progression-free survival superiority over bortezomib-based comparators, whereas FORTE, ATLAS, and IsKia address distinct questions of induction, maintenance, and antibody intensification. In relapse, ASPIRE and ENDEAVOR established benefits against historical active controls, while CANDOR and IKEMA support anti-CD38 intensification with progression-free survival gains and no established overall survival advantage. SUCCESSOR-2 supports a mezigdomide-containing strategy after lenalidomide and anti-CD38 exposure, although differing carfilzomib schedules limit attribution to mezigdomide alone. Cardiovascular, renal, infectious, logistical, and access constraints materially shape treatment value. Current data do not define an optimal sequence, and resensitisation after B-cell maturation antigen (BCMA)-directed therapy remains investigational. At relapse, the evidence for adding daratumumab or isatuximab to carfilzomib and dexamethasone applies most directly to patients naïve to both carfilzomib and anti-CD38 therapy who need a lenalidomide-sparing regimen and have sufficient cardiovascular reserve for repeated infusions.